The Improvements of the Chinese medicine system by Tyan

tingyanhe0323_ — 2023-11-07 13:15:39 UTC

The State Council has issued Document No. 44, aiming to accelerate the review and approval system reform for pharmaceuticals and medical devices. This reform is intended to promote structural adjustment and transformational upgrading in the pharmaceutical industry, and to meet the public's medication needs better.

(國務院發佈第44號文，加速推進藥品醫療器械審評審批製度改革，推動醫藥行業結構調整和轉型升級，更好地滿足公眾用藥需求。)

tingyanhe0323_ — 2023-11-08 05:54:54 UTC

Since 2016, China has been promoting the inclusion of expensive cancer treatment drugs with proven efficacy, such as Glivec, Herceptin, Mabthera, and Velcade, in the medical insurance catalog.

（2016年開始，中國推動格列衛、赫賽汀、美羅華、萬珂等療效確切但價格較為昂貴癌症治療藥品納入醫保目錄。）

tingyanhe0323_ — 2023-11-08 05:56:48 UTC

China has implemented a provisional tax rate to reduce import tariffs to zero for all general medicines, including cancer drugs, alkaloid drugs with anticancer properties, and imported traditional Chinese medicines.

（中國就以暫定稅率方式將包括抗癌藥在內的所有普通藥品、具有抗癌作用的生物鹼類藥品及有實際進口的中成藥進口關稅降為零。）

tingyanhe0323_ — 2023-11-08 05:57:44 UTC

In 2018, the National Healthcare Security Administration was established. Up to the present, the administration has carried out seven consecutive rounds of centralized volume-based procurement of national essential drugs, resulting in an average price reduction of over 50% for the selected drugs.

（2018年，國家醫保局成立，截至目前，國家醫保局連續開展7批國家組織藥品集中帶量採購，中選藥品平均降價超過50%。）

tingyanhe0323_ — 2023-11-08 05:58:30 UTC

The revised "Drug Administration Law," which was first comprehensively amended in 18 years, officially came into effect on December 1, 2019. One significant aspect of the revision was the streamlined handling of provisions related to counterfeit drugs.

（2019年12月1日新修訂的《藥品管理法》正式施行，這是18年來的首次全面修改，其中對假藥條款進行「瘦身」處理。）